SEARCH

SEARCH BY CITATION

References

  • 1
    Maki RG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 2001; 13: 2704.
  • 2
    Maki RG. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 3638.
  • 3
    Chawla SP, Staddon AP, Baker LH et al. Phase II study of mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30: 7884.
  • 4
    Pappo AS, Patel SR, Crowley J et al. R1507, a monocloncal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 2011; 29: 45417.
  • 5
    Jungbluth AA, Antonescu CR, Busam KJ et al. Monophaseic and biphasic synoviral sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001; 94: 2526.
  • 6
    Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 2008; 6: 23.
  • 7
    Ayyoub M, Taub RN, Keohan ML et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4: 7.
  • 8
    Ayyoub M, Brehm M, Metthez G et al. SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun 2003; 3: 13.
  • 9
    Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 2007; 120: 6774.
  • 10
    Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46: 15149.
  • 11
    Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 33744.
  • 12
    Yanagimoto H, Shiomi H, Satoi S et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795801.
  • 13
    Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009; 58: 184352.
  • 14
    Noguchi M, Kakuma T, Uemura H et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 10019.
  • 15
    Terazaki Y, Yoshiyama K, Matsueda S et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci 2012; 103: 63844.
  • 16
    Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10: 126679.
  • 17
    Komatsu N, Shichijo S, Maeda Y, Itoh K. Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system. J Immunol Methods 2002; 263: 16976.
  • 18
    Imanishi T, Akazawa T, Kimura A. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991, vol. 1. Oxford: Oxford Scientific Publications, 1992; 1065220.
  • 19
    Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 10919.
  • 20
    Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 337583.
  • 21
    Marigo I, Bosio E, Solito S et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32: 790802.
  • 22
    Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 227384.
  • 23
    Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 24856.
  • 24
    Minchom A, Jones RL, Fisher C et al. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma 2010; 2010: 264360.
  • 25
    Garbay D, Maki RG, Blay JY et al. Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Ann Oncol 2013; 24: 192430.